GV has thrown its weight behind Monte Rosa Therapeutics, which is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

The existing investor has chipped into the anti-fraud technology producer’s $36.3m round that lifted its overall funding to more than $60m.

Comcast Ventures was among the participants that helped increase the companionship service provider's total funding to $31m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Dell Technologies Capital has returned for a $240m series B round, having already backed a $53m series A for the silicon chip designer last November.

Lenovo Capital has chipped into the RPA software provider’s latest funding, which will go toward improving its products and entering new markets.